Literature DB >> 1132074

Identification of angiotensinogenic hypertension in man using 1-sar-8-ala-angiotensin II (Saralasin, P-113).

D H Streeten, J M Freiberg, G H Anderson, T G Dalakos.   

Abstract

Peripheral plasma renin activity (PRA) is not invariably elevated in patients whose ischemic renal lesion is causing hypertension. Infusions of an angiotensin II antagonist, 1-sar-8-ala-angiotensin II (P-113), have been used to determine whether the blood pressure responses might indicate angiotensin dependence in 221 consecutive hypertensive patients. In 32 patients P-113 infusion reversibly reduced blood pressure, and almost all of these "P-113 responders" had elevated renal vein and/or peripheral PRA levels, together with evidence of renal ischemia. Among the 189 "P-113 nonresponders," peripheral PRA was elevated in seven (3.8%), and renal vein PRA ratio was abnormal in two patients, who might represent exceptions to the otherwise successful record of the P-113 response in identifying "angiotensinoginic" hypertensives.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1132074     DOI: 10.1161/01.res.36.6.125

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  5 in total

1.  Advances in the renin angiotensin system focus on angiotensin-converting enzyme 2 and angiotensin-(1-7).

Authors:  Carlos M Ferrario; Sarfaraz Ahmad; Janae Joyner; Jasmina Varagic
Journal:  Adv Pharmacol       Date:  2010

2.  [Critical analysis of the saralasintest in the diagnosis of hypertension (author's transl)].

Authors:  A Röckel; H Wernze; B Sabel; A Heidland
Journal:  Klin Wochenschr       Date:  1977-07-01

3.  The response to the angiotensin antagonist saralasin in predicting therapeutic outcome in hypertension treated with frusemide.

Authors:  A Burke; C R George; E P MacCarthy; G S Stokes
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

4.  Renin-angiotensin system inhibition in conscious sodium-depleted dogs. Effects on systemic and coronary hemodynamics.

Authors:  C S Liang; H Gavras; W B Hood
Journal:  J Clin Invest       Date:  1978-04       Impact factor: 14.808

5.  [Saralasin-induced changes of blood pressure, renin and aldosterone in essential and renal hypertension (author's transl)].

Authors:  J Beyer; G Liebau; B Steiner; K Hayduk
Journal:  Klin Wochenschr       Date:  1978-09-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.